September 26, 2005 -- Memory Pharmaceuticals moved sharply higher on good news about its Alzheimers drug, Hollis-Eden rallied hard on speculation that its treatment for radiation syndrome will win part of the Project Bioshield contract, Corgentech fell after announcing plans to merge with privately held AlgoRx, CytRx received fast-track status for its ALS treatment, MedImmune signed a cancer deal with Georgetown University, the FDA delayed approval of a spreading agent from Halozyme Therapeutics, and Vivus got guidance but not final protocols on a pivotal trial for a sexual desire drug. The Centient Biotech 200 closed 52 points lower at 3752, a 1.37% drop. More details...
